Abstract
A secreted factor from breast cancer cells, nucleoside diphosphate kinase (NDPK) was shown to promote cell migration, proliferation, and tumor‐mediated angiogenesis, which may support metastasis. The objective of this study was to observe breast cancer development in mice in the presence of inhibitors of purinergic signaling. A luciferase‐tagged murine breast adenocarcinoma 4T1 cell line was injected into the mammary fat of immune competent BALB/C mice that were divided into treatment groups receiving a combination of ellagic acid (EA; NDPK inhibitor) and/or MRS2179 (P2Y1 receptor antagonist) or endostatin (angiogenesis inhibitor as positive control). Tumor growth was measured by imaging tumor luminescence using a Lumina II (Caliper Life Sci.). Serum samples were collected for detection of NDPK levels by enzyme‐linked immunosorbent assay. We found a significant decrease in the primary tumor growth rate at days 21 and 28 with all treatments versus the control. Future work will focus on NDPK present in the serum of women with breast cancer to support or reject the hypothesis that secreted NDPK has a role during early primary tumor and metastasis development and could serve as a biomarker of disease. (Supported by NIH HD053028)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
